| P/E (FY) | — | Sales (TTM) | $36.8M |
| Earnings (TTM) | -$341.4M | ROE | −49.63% |
| Net Margin | −314.90% | ROIC | −63.68% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 29.55% |
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule and antibody therapies for cancer, inflammatory conditions, and other diseases. Its candidates include NX-5948, an oral BTK degrader in Phase 2 trials for B-cell malignancies and autoimmune diseases; NX-2127, an oral BTK degrader; NX-1607, an oral CBL-B inhibitor in immuno-oncology trials; and NX-0479/GS-6791, an IRAK4 degrader for rheumatoid arthritis.
| Market Cap | $2.45B | Trading Days | 1360 |
| 52W High | 25.09 |
| 52W Low | 8.20 |
| % Off High | −5.92% |
| YTD | 24.41% | 1Y | 98.49% |
| 3Y | 143.05% | 5Y | −23.38% |
| Since incept. (ann.) | −8.91% |
Collaboration Revenue 64% · License Revenue 36%
| Ann. Volatility (1Y) | 62.49% | Ann. Volatility (3Y) | 70.33% |
| Sharpe (1Y) | 1.42 | Sharpe (3Y) | 0.77 |
| Max Drawdown (1Y) | −32.79% | Max Drawdown (3Y) | −70.72% |
| Beta (3Y, vs SPY) | 2.40 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc. | $2.46B | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.47B | 13.3 |
| NKTR | NEKTAR THERAPEUTICS | $2.39B | — |
| TRVI | Trevi Therapeutics, Inc. | $2.57B | — |
| VERA | Vera Therapeutics, Inc. | $2.33B | — |
| GRTX | Galera Therapeutics, Inc. | $2.61B | 25.4 |
| NUVB | Nuvation Bio Inc. | $2.29B | — |
| IMNM | Immunome Inc. | $2.62B | — |
| ATAI | AtaiBeckley Inc. | $2.64B | — |
| CUE | Cue Biopharma, Inc. | $2.65B | — |
| ALMS | ALUMIS INC. | $2.24B | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.22B | — |